Wellmarker Bio


WellmarkerBio is a company specializing in developing innovative anticancer drugs based on predictive biomarkers.

Secured 4 anticancer pipelines (colon, lung, stomach & liver cancers) and 3 biomarker pipelines (colon cancer, stomach cancer & melanoma), and has signed an MOU with ISOGENICA, UK for joint R&D; upon positive feedback on its pipelines from many overseas pharmaceutical co., technology transfer now in discussion.

In September 2022, won the ‘Good-Bio Award’ in the field of biomarker anti-cancer drugs at ‘Good-Platform Award 2022’ (4 consecutive years).